Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674849 | 0.65 | — | — | |
| SCHEMBL8042754 | 0.63 | SMN1; SMN2 (0.39) | ALDH1A1MAPTSMN1; SMN2GLAGAA | |
| SCHEMBL9970857 | 0.62 | PI4KA (0.40) | ALDH1A1POLBMAPTSMN1; SMN2GLA | |
| SCHEMBL16652843 | 0.62 | EPHX2 (0.42) | ALDH1A1POLBMAPTSMN1; SMN2GLA | |
| SCHEMBL969142 | 0.61 | KDM4E (0.43) | ALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL971946 | 0.61 | MAP4K4 (0.41) | ALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL16780344 | 0.61 | ALDH1A1 (0.36) | ALDH1A1POLBMAPTSMN1; SMN2GLA | |
| SCHEMBL971700 | 0.61 | ALDH1A1 (0.49) | ALDH1A1POLBMAPTSMN1; SMN2GLA | |
| SCHEMBL33843 | 0.60 | — | — | |
| SCHEMBL5331480 | 0.60 | RAB9A (0.51) | ALDH1A1POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | ALDH1A1 2976/4885POLB 2813/4885MAPT 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.